CTMSS

Grand Round Webinar: Research 101: What data can I report from my TMS practice, and how can I report it?
2025-05-06 20:00 - 21:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Research 101: What data can I report from my TMS practice, and how can I report it?"
Speaker: Andrew F. Leuchter, MD
rTMS is a rapidly growing area of clinical practice. Many practitioners have created innovative approaches to treatment, observed novel findings that could help improve outcomes, or discovered new potential indications for rTMS treatment. This presentation will review the types of data that can be reported in the scientific and clinical literature, how to approach creating a report, and how to find the right "home" for publication.
Key learning objectives include:

Present goals of naturalistic research in TMS practice.
Discuss different types of research report formats.
Consider what constitutes a meaningful contribution to the literature.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language

*Registered attendees will receive access to the on-demand video recording by Friday, May 9, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - May 6, 2025 at 8:00pm ET | 5:00pm PT
UK- May 7, 2025 at 1:00am BST
Australia- May 7, 2025 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
All Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event.
> >Register Now <<
About the Speaker: Andrew F. Leuchter, MD
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of
the largest academic TMS program in the country and treats patients with depression, OCD, pain, tinnitus, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.
Dr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods, and received the 2019 Outstanding Research Mentor Award from the Semel Institute.
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior, and Director of the Neuromodulation Division at the Semel Institute. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS programs, performing clinical treatment and translational research across campuses throughout Los Angeles. The dual mission of the Division is to provide care for patients with depression, chronic pain, OCD, tinnitus, and other difficult-to-treat neuropsychiatric illness, as well as enhancing treatment effectiveness, as well as clinical trials to improve treatment of depression, Post-Traumatic Stress Disorder (PTSD), and Attention-Deficit/Hyperactivity Disorder (ADHD). Dr. Leuchter’s research aims to develop novel treatment strategies and uses brain-imaging techniques, such as quantitative electroencephalography (qEEG) and magnetic resonance imaging (MRI) to examine brain function and predict which treatments are most likely to benefit individual patients.
> >Register Now <<

Minding Your Own TMS Business
2025-03-25 20:00 - 21:00 (America/New_York)
📅 March 25, 2025
📍 Virtual
Moderated by Dr. Linda Carpenter, with an all-female panel, including current CTMSS President, Dr. Martha Koo, Dr. Rebecca Allen, Dr. Carlene MacMillan and Dr. Kristin Raj.
$25 Donation. All proceeds benefit the Patient Assistance Fund.
REGISTER NOW >

Pulses - Orlando
2025-03-07 - 2025-03-09 | Omni Orlando Resort at ChampionsGate, 1500 Masters Blvd, Championsgate, FL, United States
This in-depth training course offers a certificate of completion and features lectures and over 2 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers and some special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best evidence.
Register Now

Date/Time: Friday March 7, 2025 (4pm ET) - Sunday, March 9, 2025 (3pm ET) (time is subject to change)
Location: The Omni Orlando Resort at ChampionsGate: 1500 Masters Blvd, ChampionsGate, FL 33896
The program includes:
1. An introduction to the history of and basic scientific principles of TMS by Professor Anthony Barker, who designed the first-ever TMS machine in 1985;
2. A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies;
3. Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management;
4. A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, maintenance treatment;
5. A revised lecture on TMS risk and their prevention and management, including seizure protocol review;
6. Hands-on training on coil location placement & motor threshold determination with multiple TMS devices;
7. A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain; and An extended Q & A Panel with all PULSES faculty and special guests.
8. After completion of the course, the clinician will have obtained a historical, current, and practical knowledge of the scientific basis for treating psychiatric patients with TMS.
Attendees will also have the ability to participate in an interactive Q&A Panel with Pulses faculty. Those who complete the course are awarded a certificate of completion.
Cancellation Policy:
Conference registration cancellations must be received in writing on or before February 1, 2025, to receive a refund minus a $100.00 administration fee.
Conference registration may not be transfered to a future conference.
No refunds will be issued for cancellations received after February 1, 2025.
In the event CTMSS must cancel the conference due to unforeseen circumstances, CTMSS will refund the cost of registration. However, CTMSS does not assume responsibility for any additional costs, charges, or expenses; to include, charges made for travel and lodging

Practical Ethics for TMS Practices
2025-03-04 20:00 - 21:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Practical Ethics for TMS Practices"
Speaker: Ian Cook, MD, DLFAPA, FCTMSS
Ethical issues arise every day when providing TMS therapy, whether around professionalism, boundaries, transparency, or conflicts of interest. Interactions with patients, manufacturers, colleagues, and the public may challenge us and members of our care teams. Fortunately, there are frameworks that can help us identify the issues and guide our approaches so we can uphold professional standards.
Using illustrative case vignettes, in this webinar we'll explore the ethical challenges in TMS practice with Dr. Ian Cook, long-time co-chair of the CTMSS Legal, Business, and Ethics Committee, and a Member of our Board.
During this presentation, attendees will address these three key topic areas:

Professionalism
Boundaries
Transparency and Conflicts of Interest

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available.
CE Language
*Registered attendees will receive access to the on-demand video recording by Friday, Friday, March 7, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - March 4, 2025 at 8:00pm EST | 5:00pm PST
UK- March 5, 2025 at 1:00am GMT
Australia- March 5, 2025 at 12:00pm AEDT
Cost: Members: $25 | Non-members $50 | Trainee Members FREE
> >Register Now <<
Ian Cook, MD, DLFAPA, FCTMSS

Dr. Ian A. Cook is the founding Director and CEO of the Los Angeles TMS Institute and a Professor Emeritus of Psychiatry and of Bioengineering at UCLA. His career has largely focused on improving the treatment of mental illnesses by working at the interface between medicine and technology.
In his 25+ year academic career at UCLA, he started the Unipolar Depression Research and Clinic Program, held an endowed chair in Depression Research, treated the first patient in his UCLA TMS Treatment Service in March 2009, and served as a member of the rTMS Task Group of the National Network of Depression Centers. He was Chief of Staff at UCLA’s Neuropsychiatric Hospital and was elected Chair of the Faculty of the David Geffen School of Medicine. He also was appointed Chief Translational Innovation Officer for the Semel Institute for Neuroscience and Human Behavior.
For many years he was a member of the Executive Committee on Practice Guidelines of the American Psychiatric Association, helping guide their dissemination of evidence-based practices in psychiatry. Nationally, he also served as a standing member of the NIH’s ITVA Review Committee (“Interventions Committee for Adult Disorders”).
He left UCLA in 2018 to start the Los Angeles TMS Institute and bring advanced treatment modalities out of the laboratory and into clinical care in Southern California.
Dr. Cook received his undergraduate degree in engineering from Princeton University and graduated from the Yale School of Medicine before coming to UCLA for his residency training. He then completed an NIMH T32 Research Fellowship before joining the UCLA faculty.
He is a Distinguished Life Fellow of the American Psychiatric Association and one of the inaugural Fellows of the Clinical TMS Society. He joined the Board of the Society in 2013, has been co-chair of its Legal, Business, and Ethics Committee for many years, and received the President’s Award in 2021. He is Vice President and a founding Board Member of the Foundation for the Advancement of Clinical TMS.
> >Register Now <<

Grand Rounds Webinar: Recent Advances in Neurotherapeutics for Child and Adolescent Mood Disorders
2025-02-04 08:00 - 20:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Recent Advances in Neurotherapeutics for Child and Adolescent
Mood Disorders"
Speaker: Paul E. Croarkin, DO, MS
Join Dr. Croarkin for an update on the clinical implementation and research of transcranial magnetic stimulation for adolescents with depression. Dr. Croarkin will also review recent, ongoing, and planned research focused on neurotherapeutics.
At the end of the presentation, attendees will:

Demonstrate a working knowledge of noninvasive brain stimulation modalities such as transcranial electrical stimulation, transcranial magnetic stimulation, and electroconvulsive therapy.
Demonstrate the ability to discuss recent studies adapting transcranial magnetic stimulation for adolescents with major depressive disorder.
Demonstrate the ability to discuss recent research with ketamine in adolescents and to discuss potential future studies and related challenges with psychedelic therapeutic.

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, Friday, February 7, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
One hour CME credit is available - Click here for CE Language
When:
USA - February 4, 2025 at 8:00pm EST | 5:00pm PST
UK- February 5, 2025 at 1:00am
GMT
Australia- February 5, 2025 at
12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
All Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event.
> >Register Now <<
About the Speaker: Paul Croarkin, DO, MS

Dr. Croarkin is the Ervin A. and Margaret C. Mueller Director of the Children’s Research Center at Mayo Clinic and the Chair for Pediatric
Research in the Department of Pediatrics and Adolescent Medicine. He is a professor of Psychiatry, Pediatrics, and Pharmacology in the Mayo Clinic College of Medicine and Science. He serves as the Editor-in-Chief for the Journal of Child and Adolescent Psychopharmacloogy.
Dr. Croarkin completed medical school at the University of North Texas Health Science Center. He then completed residency training in psychiatry at Naval Medical Center San Diego, where he served as chief resident. Following this, Dr. Croarkin served as a US Navy psychiatrist in an academic role at Walter Reed Army Medical Center and in an operational setting as a psychiatrist embedded with the 24th Marine Expeditionary Unit in North Babil during Operation Iraqi Freedom. He returned for clinical and research training in child
and adolescent psychiatry at UT Southwestern Medical Center in Dallas, again serving as chief resident. He earned a Master of Science degree with distinction in clinical science from the Graduate School of Biomedical Sciences at UT Southwestern Medical Center. Thereafter, he joined the Mayo Clinic Department of Psychiatry and Psychology.
An expert in child, adolescent, and adult mood disorders, neurotherapeutics, and psychopharmacology, Dr. Croarkin conducts research to develop innovative diagnostic and treatment approaches for children and adolescents. His research has been funded by the National Alliance for Research on Schizophrenia and Depression, the National Institutes of Health, and industry partnerships. His team focuses on adapting and innovating neurotherapeutics for youth with psychiatric disorders while studying GABAergic and glutamatergic
neurotransmission. These efforts have informed and supported the clinical implementation of transcranial magnetic stimulation interventions for adolescents with depression. His findings have been published in numerous peer-reviewed journals, including The Journal of the American Academy Child and Adolescent Psychiatry, JAMA Psychiatry, and Neuropsychopharmacology.
> >Register Now <<

Grand Rounds Webinar: "Oops, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse
2025-01-07 20:00 - 21:00 (America/Los_Angeles) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Oops, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse.
Speaker: Colleen A. Hanlon, PhD
Join us for an insightful session on Transcranial Magnetic Stimulation (TMS) as an innovative treatment for addiction. This session will explore the FDA approved use of TMS for smoking cessation, European clearance for stimulant use disorder, and emerging evidence supporting its application in alcohol use disorders. Learn about the mechanisms of action, current clinical research, and practical strategies for integrating TMS into your addiction treatment protocols. Designed for physicians and mental health providers, this session will provide valuable insights into how TMS can enhance patient outcomes and expand treatment options for substance use disorders.
At the end of the presentation, attendees will:
- Identify the current FDA indication for TMS in smoking cessation and discuss the emerging evidence supporting its use in stimulant and alcohol use disorders.
- Describe the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use.
- Evaluate the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use.
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, January 10, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
One hour CME credit is available - Click here for CE Language
When:
USA - January 7, 2025 at 8:00pm EST | 5:00pm PST
UK- January 8, 2025 at 1:00am GMT
Australia- January 8, 2025 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
All Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event.
> >Register Now <<
About the Speaker: Colleen A. Hanlon, PhD

Vice President, Medical Affairs, BrainsWay
Professor (adjunct), Wake Forest University School of Medicine
Dr. Hanlon is an internationally recognized thought-leader in the development and expansion of non-invasive neuromodulation therapeutics for new populations.
She is currently serving as the Vice President of Medical Affairs for BrainsWay and Director of their Innovation Team. Before coming to BrainsWay she was a tenured professor at the Wake Forest School of Medicine. There she ran a multidisciplinary research program devoted to developing brain-circuit based interventions for individuals struggling with drug and alcohol use disorders. She has nearly 20 years of clinical research experience in transcranial magnetic stimulation (TMS) and brain imaging. Recognized as a pioneer int TMS for addiction, Dr. Hanlon received over $12 million in National Institute of Health funding, led over 15 clinical studies of TMS, published over 100 peer-reviewed publications, and mentored over 75 trainees in brain imaging and TMS.
She received her undergraduate degree from the University of Florida, a Ph.D. in neurobiology from Duke University wherein she focused on motor recovery after stroke and in Parkinsons Disease using functional MRI. She did a postdoctoral fellowship at Wake Forest University wherein she first became interested in neuromodulation.
In 2023, she was given the prestigious International Brain Stimulation Early Career Investigator award and she is the senior author on the first “Consensus Paper” published by a group of over 70 scientists from over 10 countries outlining the path forward for Non-Invasive Therapeutic Development for Addiction.
In addition to advancing the science and evidence for TMS for various indications, she also participates in the research training and education community at local, national, and international levels. She has directed the Advanced TMS Training Course sponsored by the National Center for Neuromodulation for Rehabilitation and has served on the grassroots Advocacy committee and Public Policy committees of several scientific organizations devoted to expanding access to care for individuals with drug and alcohol use disorders.

> >Register Now <<

Non-Invasive Brain Stimulation to Treat Chronic Pain Targets, Mechanisms and Clinical Outcomes
2024-11-12 12:00 - 13:00 (America/New_York)
> >Watch Now <<
You are invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series, Non-Invasive Brain Stimulation to Treat Chronic Pain Targets, Mechanisms and Clinical Outcomes, presented by Daniel Ciampi de Andrade, MD, PhD.
Dr. Daniel Ciampi de Andrade is a clinical neurologist currently focused on teaching and doing research on chronic pain. He has a strong interest on the use of rTMS for the management of neurological diseases, chronic pain in particular. As rTMS enter guidelines for the managements of chronic pain, Dr. Daniel Ciampi de Andrade will provide an update on the mechanisms of action of rTMS for pain management, and how it can be used to aid people with chronic pain in their quest for adequate pain relief.
At the end of this presentation, attendees will:

Have a clear understanding on how chronic pain syndromes are classified.
Have a general knowledge of the treatment options for the most common pain syndromes.
Understand how neuromodulation, in particular rTMS, can be added to the treatment plan as backed up by evidence.

Take advantage of our live Q&A session at the conclusion of the webinar.
One hour CME credit is available - Click here for CE Language
Date/Time:
USA - November 12, 2024 at 12:00pm EST | 9:00am PST
UK- November 12, 2024 at 5:00pm GMT
Australia- November 13, 2024 at 4:00am AEDT
Format: Live Webinar
Cost: Members: $25 | Non-members $50 | Trainee Members FREE
Can't make this time and date? All Grand Rounds are recorded and available On-Demand to all registered attendees. Recordings are available Friday after the live event.

Speaker: Daniel Ciampi de Andrade, MD, PhD

Dr. Daniel Ciampi de Andrade is an associate professor and researcher at the Center of Neuroplasticity and Pain, Department of Health Science and technology and Faculty of Medicine, Aalborg University, Denmark.
Dr. Daniel Ciampi de Andrade trained as a clinical neurologist at the University of Sao Paulo, Brazil, and in France (Université Paris-Saclay /Université Paris XII). He trained with Didier Bouhassira, Nadine Attal and Jean-Pascal Lefaucheur during his stay in Paris, France, coming back to Sao Paulo, Brazil in 2009. He then was appointed coordinator of the Multidisciplinary Pain Center of the Neurology Department, at the University of Sao Paulo. This center was founded by his mentor, Professor Manoel Jacobsen Teixeira, in 1974 and is one of the largest pain centers in Latin America. Dr. Daniel Ciampi de Andrade co-founded and was vice chair of the Medical Research Laboratory of “invasive neuroscience” from 2019 to 2021.
In 2021 he moved to Aalborg and joined CNAP. His research has been focused on pain in neurological diseases and neuromodulation for pain relief. In particular, he has performed research on how pain can influence cortical connectivity and how this information can be used to inform personalized treatment approaches.
Dr. Daniel Ciampi de Andrade has been serving as Vice-Chair of EFIC´s Research Committee since 2024, section editor of the European Journal of Pain since 2016, and advisory Board of Pain Reports since 2018. He as published more than 180 peer-reviewed studies, along with pain book editing and several international book chapters. He received a European Research Council grant that will allow him to continue research, paired with an amazing team of colleagues at CNAP, to further explore the effects of pain in the human brain.
> >Watch Now <<

When
November 12th, 2024 from 9:00 AM to 10:00 AM

Location

United States

Contact

Phone: info@clinicaltmssociety.org
Email: info@clinicaltmssociety.org

Event Fee(s)

Fee Level

Webinar Registration | Member
$25.00

Webinar Registration | Non-Member
$50.00

Webinar Registration | Student
$0.00

Webinar Registration | Associate Member
$25.00

Speaker Price
-$50.00

CTMSS On-Demand Webinar: An Introduction to TMS
2024-11-07 08:00 - 17:00 UTC
>>WATCH NOW<<
*NEWLY UPDATED* CTMSS On-Demand Webinar: An Introduction to TMS
Release Date: January 1, 2023
Expiration Date: December 31, 2024
The Clinical TMS Society is offering a 4 part on-demand webinar focused on the introduction to TMS.
CTMSS On-Demand Webinar: An Introduction to TMS is geared primarily for new clinicians and TMS operators/technicians. In addition, experienced clinicians and technicians who seek a stronger knowledge base would also benefit from the review and updates.
Participants will learn:

the history of rTMS, including a knowledge of indications, clinical efficacy, review of data;
a review of the significant scientific literature giving rise to the technology's adoption;
an understanding of practical office implementation;
a review of the evidence for conditions other than depression

Format: On-Demand Webinar
Cost:

CTMSS Members | $150 USD
Non-members | $300 USD

You will receive immediate access to the video.

Presenters:

Debra Stultz, MD, FCTMSS
Dr. Debra J. Stultz is the Director and Owner of Stultz Sleep and Behavioral Health in Barboursville, West Virginia. Dr. Stultz earned her medical degree from Marshall University School of Medicine in Huntington, West Virginia. She completed a residency in psychiatry and a fellowship in child/adolescent psychiatry through West Virginia University at their Charleston Division through Charleston Area Medical Center in Charleston, West Virginia. She is board certified in psychiatry, sleep medicine, and behavioral sleep medicine. With a special interest in Narcolepsy, she treats a variety of sleep disorders and psychiatric issues. Her specialty in psychiatry is treatment-resistant depression. She is also the editor for the Clinical TMS Society Newsletter, on their Board of Directors, Co-Chair of the Education Committee, and the chairman of the TMS and Sleep Disorders Affinity Group.

Jonathan Becker, DO
Dr. Becker completed his undergraduate and Masters degrees in Developmental Psychology at Tulane University in New Orleans before attending Des Moines University for medical school. He completed his psychiatry residency program at Vanderbilt University and served as a faculty member there for 7 years. While at Vanderbilt, Dr. Becker served as the medical director of the neuromodulation service from 2017 – 2022. He joined the Neuroscience and TMS Treatment Center in Brentwood, TN in January 2021. He is an active member of the Clinical TMS Society and a member of the Education Committee.

Nicholas Mischel, MD, PhD
Dr. Mischel is an Assistant Professor and Director of Interventional Psychiatry and Neuromodulation Research at Wayne University School of Medicine, in their Department of Psychiatry and Behavioral Neurosciences. He completed his psychiatry residency at Duke University Medical Center, focusing on brain stimulation clinical/translational research. He now focuses on medication-resistant mood disorders using rTMS and rapid-acting antidepressant medication infusions. He is a member of the Clinical TMS society and is on the Outreach and Education Committees.
Sandeep Vaishnavi, MD, PhD
Dr. Vaishnavi received his medical degree from the University of Alabama at Birmingham and completed his residency at Duke University. He completed a visiting fellowship in Transcranial Magnetic Stimulation at Duke University. He is an Adjunct Associate with the Department of Medicine-Pulmonary at Duke University, is a faculty member with the Duke Visiting Fellowship program in Transcranial Magnetic Stimulation, is a member of the faculty network for the Duke Institute for Brain Sciences, is Director of Mindpath Care Centers Clinical Trails Institute, and a member of the Corporate Governance Board for MindPath Care Centers. He is a member of Clinical TMS Society and is on the Education Committee.

Residents, Trainee Doctors, & Medical Students | CTMSS Education Slide Deck: Transcranial Magnetic Stimulation (TMS) - An Introduction
2024-11-07
>>WATCH NOW<<
Learning objectives:
Part 1: TMS in Depression

Understand the evidence for transcranial magnetic stimulation (TMS) as a treatment for depression
Describe where TMS falls in a major depressive disorder (MDD) treatment algorithm
Know the history of TMS
Understand potential mechanisms of actions of TMS
Know the efficacy rate of TMS for MDD from scientific literature

Part 2: Beyond Depression

Know FDA cleared psychiatric indications for TMS
Understand the basic neurobiology of OCD and addictions as related to the potential mechanism of TMS
Review the data supporting the use of TMS for OCD and smoking cessation
Identify the potential risks of TMS
Understand patient appropriateness for TMS based on demographics, diagnosis, and treatment history

Cost: Free
Please register to view the presentation. On-demand video will populate at the bottom of this page once registered. To access the powerpoint presentation slide deck, you must also complete the Education Slide Deck Member User Agreement. At the bottom of this recording you will be prompted to complete a brief survey.

Speakers: Kristin Raj, MD & Suzanne Kerns, MD
Dr. Raj specializes in the treatment of mood disorders with expertise in neuromodulation and in the psychopharmacological management of the bipolar disorder. She is Chief of Interventional Psychiatry and Chief of the Bipolar Clinic at Stanford University. She is the director of education for interventional psychiatry where she manages resident and fellow education in brain stimulation and the development of didactics. She is also director of the neuroscience curriculum for the psychiatry residency where she has worked to create and assess a new series of interactive lectures. She trained in biomedical engineering in undergraduate at Case Western Reserve University and completed her medical degree and psychiatry residency at Stanford University. She currently serves on the Board of Directors and the Education Committee of the Clinical TMS Society.
Dr. Kerns completed her undergraduate studies at the University of North Carolina in Chapel Hill. She attended medical school at the University of Sydney in Australia, followed by a psychiatry residency at Duke University Medical Center. Dr. Kerns subsequently completed a year-long Fellowship in Brain Stimulation at the Medical University of South Carolina (MUSC) under the guidance of Dr. Mark George, a founding father of TMS. After several years of private practice at Seattle Neuropsychiatric Treatment Center with a faculty appointment at the University of Washington, she returned to MUSC, where she is now an Assistant Professor of Psychiatry on the Brain Stimulation Service. Dr. Kerns is a past member of the Board of Directors of the Clinical TMS Society, past Member-at-Large on the CTMSS Executive Committee, past Co-Chair of the CTMSS Education Committee, and she continues to proudly serve as a member of the Education Committee and Resident Education Task Force for the Clinical TMS Society.

If you have any questions, please email: info@clinicaltmssociety.org

On-Demand Webinars Library
2024-10-21 | Zoom

Apples and Oranges: Comparative Effectiveness Research in TMS
2024-10-01 08:00 - 17:00 UTC | Zoom
> > Register Now <<
Although not labeled as such by the FDA, TMS is considered a third line treatment by many practitioners and health insurance company policies. Earlier referral to TMS is not commonly practiced but may be non-inferior to or superior to medication switches or augmentation. Our field lacked trials that compared different modalities of treatment in parallel with TMS until recently, which is the subject of this webinar.
The core aspect of this webinar will be reviewing two very recent articles that compare TMS to antidepressant medications. We will also review basic concepts of non-inferiority trials and meta-analyses.
At the end of the presentation, attendees will be able to:

Understand "head-to-head" trials and meta-analyses research.
Review and understand recent comparative articles on TMS.
Review and understand the current and future placement of TMS in the treatment algorithms of depression.

Format: On Demand Webinar
Cost: Members: $25 | Non-members $50 | Trainee Members FREE
Speaker: Mehmet Dokucu, D, PhD, DFAPA

Dr. Dokucu is a broadly trained neuroscientist (PhD) and academic psychiatrist (MD) with expertise in Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Consultation Liaison Psychiatry and Psycho-oncology. He was the founding director of the Transcranial Magnetic Stimulation program at Northwestern Medicine in Chicago. He is currently an Associate Professor of Psychiatry at Dartmouth Geisel School of Medicine and he currently directs the Mood Disorders and Interventional Psychiatry Program at Dartmouth Hitchcock Medical Center.
> > Register Now <<

September 10, 2024 Town Hall Member Meeting
2024-09-10
Join the Clinical TMS Society President Martha Koo, MD, FAPA, FASAM, FCTMSS, committee co-chairs, and other Society volunteers for an update on current activities.
This is your opportunity to learn more about the Society's various goals and projects.
>>MEMBER WATCH NOW<<

Stimulating for Hope: Transcranial Magnetic Stimulation for Patients at Risk for Suicide
2024-09-03 08:00 - 09:00 UTC
> > Register Now <<

The United States is in the midst of a crisis of suicide, and TMS providers often must confront this directly. In this presentation, Dr. Philip will provide a brief overview of the existing TMS protocols used to reduce suicidal ideation, reviewing their efficacy and also burden of administration. He will describe an ongoing clinical trial combining TMS plus psychotherapy for PTSD, and outline his own clinical approach to treating suicidal patients, so that attendees can consider how they can address this critically important issue.
At the end of the presentation, attendees will be able to:

Describe various evidence-based TMS parameters to treating patients at higher suicide risk.
Demonstrate understanding of the interaction (or lack thereof) between changes in depression and suicidal ideation during TMS.
Discuss future TMS options in high risk patients.

Format: On-Demand Webinar
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Noah S. Philip, MD

Dr. Philip is a Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. He is the founding Section Chief of Psychiatric Neuromodulation at VA Providence, and is Lead for Mental Health Research at the VA RR&D Center for Neurorestoration and Neurotechnology.
Dr. Philip received his BSc from McGill University and his MD from Albany Medical College where he graduated AOA and with a Distinction in the Study of Biomedical Ethics. He completed his psychiatry residency training at Brown University, followed by T32 and Neuromodulation Fellowships at Brown.
Dr. Philip’s laboratory uses a precision approach to new and emerging technologies, with the goal to understand and treat posttraumatic stress disorder, major depression, and suicidality. His research has been featured in JAMA Psychiatry, American Journal of Psychiatry, Biological Psychiatry, and the National Neuroscience Curriculum Initiative (tDCS+Virtual Reality for PTSD). He is currently conducting an NIMH-funded cooperative study to perform a first-in-human study investigating MRI-guided low intensity focused ultrasound for depression and anxiety (U01 MH123427).
Dr. Philip has received awards and recognition from the American Psychiatric Association, Society for Biological Psychiatry, American College of Neuropsychopharmacology, and others. He has been funded through grants from the VA (Rehabilitation, Clinical Science, and Health Services R&D), NIMH, NIDA, Department of Defense, and through industry and small-business collaborations. He is active in several national organizations, including SOBP and ACNP, and is a past President of the Psychiatric Research Society.
Dr. Philip plays a significant training and mentoring role at Brown, where he is Associate Director of the NIMH R25 psychiatry resident research training program, and serves as a mentor through national organizations such as the Career Development Institute for Psychiatry. He is committed to action to improve diversity, equity, inclusion, and belonging.

> > Register Now <<

What Does a TMS Doctor Need to Know About Brain Networks?
2024-08-06 20:00 - 21:00 UTC
> > Register Now <<
Network neuroscience is becoming increasingly relevant to the clinical practice of TMS, but it is a large and complicated field that is impossible for a clinician to follow comprehensively. This lecture will provide a basic foundation of brain networks and describe general principles for how to recognize when a new development in this field is clinically useful.
At the end of this presentation participants will:

Define specific brain networks currently involved in TMS targeting.
Appraise new network-based TMS targets to determine when they are ready for clinical practice.
Recognize which brain network studies are not clinically useful yet.

One Hour CME Credit Available
Format: On-Demand Webinar
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Shan H. Siddiqi, MD

Dr. Siddiqi is an assistant professor of psychiatry at Harvard Medical School, a neuropsychiatrist at Brigham & Women’s Hospital, and director of psychiatric neuromodulation research for the Center for Brain Circuit Therapeutics. His research is focused on causal mapping of human brain function and dysfunction. Using techniques such as functional MRI, his lab maps brain circuits to link brain lesions and brain stimulation sites that can modify different psychiatric symptoms. These circuits can then be targeted with treatments such as TMS to alleviate symptoms in psychiatric disorders. His work has been recognized with multiple awards from the National Institute of Mental Health, the Brain & Behavior Research Foundation, the American Neuropsychiatric Association, the American College of Neuropsychopharmacology, Harvard Medical School, and many others.
> > Register Now <<

What’s the Secret Recipe? Treating Depression with TMS in the Era of Accelerated Protocols and Functional MRI Targeting
2024-07-02 20:00 - 21:00 UTC
Methods for enhancing the antidepressant effects and treatment efficiency of transcranial magnetic stimulation have advanced rapidly in the past several years, with new FDA-cleared protocols and promising early data. Dr. Trapp will discuss the evidence for various TMS optimization procedures with a focus on trying to understand the “secret recipe” for delivery of the most efficacious TMS treatment protocol.
During this presentation participants will:

Discuss current methods and considerations for TMS targeting of the DLPFC for depression treatment.
Discuss current evidence for dose-response effects and accelerated TMS protocols for depression.
Review methods and data for optimizing the antidepressant effects of TMS.

One Hour CME Credit Available
Format: Webinar
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Nicholas T. Trapp, MD

Dr. Trapp is an Assistant Professor of Psychiatry at the University of Iowa, where he is the Director of the Interventional Psychiatry Program and the Neuropsychiatry Clinic. He completed psychiatry residency at Washington University in St. Louis, followed by post-doctoral fellowship in neurostimulation and neuroimaging at the University of Iowa and behavioral neurology/neuropsychiatry at Stanford University. His research focuses on the targeting, application, and optimization of neuromodulation therapies for the treatment of psychiatric conditions. Projects have included novel TMS clinical trials, mechanistic TMS studies, and lesion-network mapping of psychiatric symptoms to identify candidate brain stimulation targets. He also leads the TMS for Depression Consensus Recommendations Work Group as part of the National Network of Depression Centers Neuromodulation Task Group and serves on the Clinical TMS Society Research Committee. Clinically Dr. Trapp evaluates patients for TMS, ECT, DBS, VNS, and esketamine. He has received Career Development Awards from the National Institutes of Mental Health and the American Neuropsychiatric Association, as well as a Young Investigator Award from the Brain and Behavior Research Foundation. His current research funding is to study the electrophysiologic effects of TMS in epilepsy patients with intracranial recording electrodes.

The Unique Case of Bipolar Depression and Transcranial Magnetic Stimulation
2024-05-07 17:00 - 18:00 UTC
> > Register Now <<
There are few level 1 evidence based treatments for bipolar depression, and when these are either ineffective or poorly tolerated alternative non-pharmacological treatments are required. Non-invasive neurostimulation, in particular transcranial magnetic stimulation, is a treatment option for difficult to treat depression that is of interest in bipolar depression. In 2020, the FDA granted breakthrough designation for TMS for bipolar depression, however if it does receive approval it remains to be determined where TMS belongs in the bipolar depression algorithm. Here, we will review the management of bipolar depression, and review the peer reviewed literature using TMS to treat bipolar depression. In particular, the conflicting data will be contextualized within the unique biological and pharmacological constraints that characterize bipolar disorder.
At the end of this presentation participants will:

Understand the current management of bipolar depression.
Review the clinical trial and open label literature using TMS to treat bipolar depression.
Appreciate the complex interplay between biology and pharmacology that makes TMS in bipolar disorder unique.

1 CME Credit Available
Format: Webinar
Cost: Members: $25 | Non-members $50 | Student Members FREE

Speaker: Alexander McGirr, MD, PhD, FRCPC
Alexander McGirr received his MSc in neuroscience at McGill University under Dr. Gustavo Turecki before pursuing medical school at the University of Toronto. There, in addition to medical studies he pursued basic science training under Dr. John Roder. His research track psychiatry residency at the University of British Columbia, where his clinical research in mood disorders was under Drs. Lam and Yatham, included a contemporaneous PhD in Neuroscience under Dr. Timothy Murphy. His independent research includes two fronts: 1) a human research program that is both pre-clinical and clinical using non-invasive brain stimulation to probe and treat neuropsychiatric illness, and 2) a basic science program using animal models and next gen technologies for circuit dissection and to understand how risk factors related to neuropsychiatric illness change neural circuitry in an effort to inform treatments in humans.
> > Register Now <<

Electroconvulsive Therapy: How to Make a Highly Effective Treatment More Acceptable
2024-04-02 08:00 - 21:00 UTC
> > Register Now <<
Electroconvulsive therapy (ECT) is a highly effective treatment for major depression. However, it is underused due to stigma and concern over its side effects on memory. This webinar will describe the history of ECT including its many improvements over more than 80 years. This will be followed by a presentation of recent research that aims to make ECT more acceptable by minimizing its side effects on memory through better understanding of the mechanisms of its therapeutic effect on depression and its adverse effects on memory.
At the end of this presentation participants will:

Be familiar with the history of ECT including its improvements over more than 80 years.
Be aware of the therapeutic effect of ECT on major depression and the adverse effect of ECT on memory.
Learn of new research into the mechanisms of the therapeutic and adverse effects of ECT that aims to make ECT more acceptable by minimizing its side effects on memory.

1 Hour CME Credit Available
Format: Webinar
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: William T. Regenold, MDCM

William T. Regenold, MDCM is a board certified general and geriatric psychiatrist. He is a Senior Research Physician and the Medical Director of the Noninvasive Neuromodulation Unit (NNU) in the Experimental Therapeutics and Pathophysiology Branch of the National Institute of Mental Health (NIMH). At the NIMH, he collaborates with a research team investigating electroconvulsive therapy and transcranial magnetic stimulation, primarily in the treatment of major depression. Dr. Regenold studied medicine at McGill University in Montreal. He trained in Medicine, Neurology and Psychiatry at the Johns Hopkins Bayview Medical Center in Baltimore and in Psychiatry and Old Age Psychiatry at the Johns Hopkins Hospital in Baltimore and the Maudsley Hospital in London. Prior to joining the NIMH, he was at the University of Maryland Department of Psychiatry where he was Director of the Division of Geriatric Psychiatry, the Adult Inpatient Service, and the Electroconvulsive Therapy Service. His research at the University of Maryland focused on mood disorder pathophysiology and electroconvulsive therapy.
> > Register Now <<

Research and Clinical Applications of TMS in Pediatric and Neurodevelopmental Populations
2024-03-05 08:00 - 21:00 UTC
> > Register Now <<
The CDC currently estimates that nearly 1 in 5 children have a developmental or psychiatric disorder; yet evidence-based, targeted treatments for these disorders are lacking.
Taking an Experimental Therapeutics approach, the research that will be discussed aims to understand the mechanisms that contribute to dysfunctional development of neural systems associated with symptoms of pediatric psychiatric and neurodevelopmental disorders utilizing neuroimaging and neurophysiological tools combined with transcranial magnetic stimulation interventions. The ultimate goal of the research that will be discussed is to inform the development of novel targeted device-based treatment strategies. Though there is much promise for these targeted device-based interventions, data on the safety and efficacy of these interventions in pediatric and neurodevelopmental populations is limited. The current state of the research will be reviewed and future directions for the field will be discussed.
At the end of this presentation participants will be able to:

Review the findings of studies using TMS to probe physiology in autism spectrum disorder (ASD).
Describe how TMS can be used to induce long-term changes in brain network functioning and potentially treat pediatric neuropsychiatric and behavioral disorders.
Identify potential network targets where applying TMS may be effective for reducing transdiagnostic symptom domains commonly seen in neuropsychiatric and behavioral disorders.

1 Hour CME Credit Available
Format: Live Webinar
Cost: Members: $25 | Non-members $50 | Student Members FREE

Speaker: Lindsay Oberman, PhD

Dr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time, she has published over 60 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism, mood disorders, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation, sensory processing, social cognition, and executive functioning across disorders. In doing so, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.
> > Register Now <<

Controlling Brain State Variability to Optimize rTMS Efficacy
2024-02-06 19:00 - 20:00 (America/Chicago)
> > Register Now <<
The Clinical TMS Society presents this installment of our Grand Rounds Webinar Series: Controlling Brain State Variability to Optimize rTMS Efficacy featuring Speaker: Lysianne Beynel, PhD
In this presentation, we will explore the pivotal role of brain state variability in influencing basic TMS outcomes like MEP and phosphenes. We will then focus on some clinical applications that used control of state-dependency as a proof of principle. Finally, in a demonstration of a specific case of state-dependency control, we will uncover the potential synergy between rTMS and cognitive therapy in
improving depression treatment, as a way to pave the way for more personalized and effective therapies.
At the end of this presentation participants will be able to:
• Demonstrate how varying brain states affect basic TMS measures like motor
evoked potentials (MEPs) and phosphenes.
• Evaluate the impact of controlling brain state on improving rTMS outcomes as
a proof of principle.
• Examine the potential benefits of combining rTMS with cognitive therapy for
treating depression in this context.
Take advantage of our live Q&A session at the conclusion of the webinar!
1 Hour CME Credit available
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

Speaker: Lysianne Beynel, PhD
Dr. Beynel completed her PhD at University Grenoble Alpes in France where she
investigated the effects of transcranial magnetic stimulation (TMS) on bipolar
disorders. She then moved to Duke University for her post-doc work, where she
investigated the use of rTMS in improving working memory in older adults. Her
research, at that time, was mainly focused on the effects of ‘online’ TMS, i.e., applying
stimulation while participants were performing a task, as a potential means to further
engage the stimulated network and produce stronger effect. She is now a Research
Fellow at the NonInvasive Neuromodulation Unit (NNU) in the Experimental
Therapeutics and Pathophysiology Branch of the National Institute of Mental Health,
where she is combines two of these skill sets to apply TMS during cognitive therapy to
improve outcomes in depressive disorders. Dr. Beynel is also exploring the potential
of combining real-time fMRI neurofeedback with rTMS to achieve more precise control
over brain state.

> > Register Now <<

TMS Documentation: Expert Perspectives
2024-01-09 08:00 - 21:00 UTC
> > Register Now <<
The CTMSS Insurance Committee presents: "TMS Documentation: Expert Perspectives". In this panel discussion, we will discuss the range of approaches when it comes to documenting TMS sessions. We will also explore how the documentation serves multiple purposes for different audiences: clinical and administrative staff, patients, payers, and the court.
At the end of this presentation, participants will be able to:

describe the core elements of a TMS procedure note in order to adequately convey clinical information to others involved in the care of a patient.
understand the range of approaches to documentation of TMS sessions and the benefits and limitations of each approach.
develop an approach to documentation of TMS sessions for your practice that meets the expectations of relevant insurance plans and malpractice carriers.

This Grand Rounds Webinar will highly encourage audience participation!
1 Hour CME Credit available
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

Panelists:
Sam Huber, MD, MS

Dr. Huber is an experienced physician executive and clinical psychiatrist. He holds degrees from the University of Rochester, University of Rochester School of Medicine, and the Dartmouth Institute for Health Policy and Clinical Practice. He trained at Washington University in St. Louis and the White River Junction Vermont VA Medical Center. He has served as Medical Director for Inpatient Psychiatry, Medical Director for Interventional Psychiatry, and Associate Quality Officer at the University of Rochester Medical Center, Associate CMO for Patient Safety and Quality at Rochester Regional Health (Rochester, NY), and Chief Medical Officer for MultiCare Behavioral Health-MultiCare Health System (Tacoma, WA). He has clinical experience across the spectrum of acute services including short and long-term inpatient, emergency psychiatry, consultation/integrated care, neuromodulation (ECT, TMS) and adult ambulatory psychiatry. As Medical Director for Interventional Psychiatry, Dr. Huber partnered with multiple divisions and stakeholders to sustain a margin-positive ECT service and launch the Rochester region’s first TMS service within a health system.
Shelly Lahn, MBA

Shelly Lahn is the CEO of Neuro Wellness TMS Centers of America where they specialize in transcranial magnetic stimulation (TMS).

CTMSS Insurance Committee member
National Ketamine Task Force member
Owner/Operator/Founder of Neuro Wellness Centers of America using Apollo TMS Machines

Rebecca Allen, MD, MPH

Dr. Allen graduated with a B.A. in Psychology with honors from Stanford University. She attended Oregon Health and Science University for medical school where she also earned a Masters of Public Health in biostatistics and epidemiology. She completed psychiatry residency at the Harvard Longwood Psychiatry Residency Training Program, a joint program between Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, and Massachusetts Mental Health Center. She served as Chief Resident of the psychiatry consult service at Beth Israel Deaconess Medical Center. She then went on to complete a 2-year fellowship in Neuropsychiatry at Brigham and Women’s Hospital. She has participated in research on sleep and memory consolidation, quality of life in multiple sclerosis, efficacy of different TMS protocols, EEG biomarkers of TMS response, the RECOVER VNS trial, and other projects. She has authored several papers.
Moderator:
Carlene MacMillan, MD

Dr. MacMillan is the Chief Medical officer at Osmind. Osmind is a technology platform that helps clinicians who provide breakthrough mental health treatments track outcomes and document interventions. She is the Co-Chair of the Clinical TMS Society Insurance Committee and on the Board of Directors of the Clinical TMS Society. She participates in neuromodulation clinical trials and post-marketing research. She completed her medical training at Harvard medical school and her adult psychiatry residency and child psychiatry fellowship at Massachusetts General Hospital and McLean Hospital.
> > Register Now <<

Precision Organizational and Functional Estimates for TMS Targeting
2023-12-05 20:00 - 21:00 UTC
> > Register Now <<
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Precision Organizational and Functional Estimates for TMS Targeting featuring Dr. Mark Eldaief!
Network models are increasingly invoked to characterize the neurobiological underpinnings of mental illnesses. Dysfunction within specific networks (e.g., the default, salience and control networks) promotes the formation of specific symptoms. This suggests an opportunity to treat specific depressive symptoms by modulating specific circuits with transcranial magnetic stimulation (TMS). In this talk, I will review our project which uses precision MRI methods to delineate cortical networks in the individual at high resolution and to then stimulate specific networks in separate sessions with TMS. We will then survey the differential impact of network-specific stimulation with REST-BOLD and TASK-BOLD imaging as well as with validated state-based questionnaires and brief neuropsychological tests. This work will facilitate individualized neuromodulation approaches based on network topography. This will pollinate large-scale clinical trials assessing the effects of differential circuit modulation. It will also illuminate circuit-construct relationships across neuropsychiatric disorders.
At the end of this presentation participants will be able to:

describe the network basis of specific psychopathological symptoms in depression.
identify the use of precision MRI to define cortical networks in the individual.
list the methods of applying TMS to specific networks in the individual to modulate specific symptom domains.

1 Hour CME Credit available
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKERS:
Mark Eldaief, MD

Dr. Eldaief attended medical school at Columbia University. Following this, he did a combined residency in Neurology and Psychiatry at Columbia and a Research Fellowship in Cognitive Neurology at the Beth Israel Deaconess Medical Center. He is now an Assistant Professor of Neurology at Harvard Medical School and is a staff neurologist and psychiatrist at the Massachusetts General Hospital.

> > Register Now <<

Vagus Nerve Stimulation: What Do We Have When All Treatments Have Failed?
2023-11-07 20:00 - 21:00 UTC
> > Register Now <<
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Vagus Nerve Stimulation: What Do We Have When All Treatments Have Failed? featuring Dr. Scott Aaronson!
Despite compelling evidence for efficacy, vagus nerve stimulation has languished due to problems with the design of two randomized clinical trials which led to a non coverage determination (NCD) made by in Centers for Medicare and Medicaid (CMS) in 2007. After a seminal comparative observational study was published in 2017, CMS agreed to rescind its NCD and agreed to fund a coverage with evidence development study for up to 1000 participants with either unipolar or bipolar depression. The unipolar arm of the one year study will be completed in the Spring of 2024. In preparation for the potential clinical availability of VNS, we will review the proposed mechanism of action, identify appropriate candidates, review the existing outcomes data and discuss the advantages and disadvantages of this unique albeit invasive treatment approach for the most severely treatment resistant depressions.
At the end of this presentation participants will be able to:

describe the proposed mechanism of action for VNS
identify potential candidates for the use of VNS
list the most frequent adverse events found in the use of VNS

1 Hour CME Credit available
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKERS:
Scott T. Aaronson, MD, DLLAPA, FCTMSS

Dr. Scott Aaronson is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine, distinguished life fellow of the American Psychiatric Association, and is a fellow of the American College of Psychiatrists. Dr. Aaronson also serves/served on the boards of the American Society of Clinical Psychopharmacology and the Clinical TMS Society.
In addition to his work at The Retreat, Dr. Aaronson is the director of clinical research programs at Sheppard Pratt, where he is the principal investigator for multiple studies on the development of therapies for mood and anxiety disorders. He has particularly been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS) and Vagus Nerve Stimulation (VNS)—in the treatment of severe refractory mood disorders. Most recently, he was named the Chief Science Officer of the Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics, focused on the development of uses for psychedelic medications across the spectrum of psychiatric illness.

> > Register Now <<

Neuromodulation for the Traumatized Brain: Modulating Dysfunctional Neural Networks in PTSD
2023-10-03 20:00 - 21:00 UTC
> > Register Now <<
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Neuromodulation for the Traumatized Brain: Modulating Dysfunctional Neural Networks in PTSD featuring Dr. Sandeep Vaishnavi! In this presentation, Sandeep Vaishnavi, MD, PhD will discuss the neural networks involved in stress and fear responses thought to be dysfunctional in PTSD. He will review nodes in these networks that could be modulated by TMS. He will then review the current state of evidence of TMS for PTSD, including figure-of-8 coil, H-coil, and theta burst studies. At the end of this presentation participants will be able to:

describe the neural networks thought to be dysfunctional in PTSD
explain the strategies used to modulate nodes in these dysfunctional networks
understand the current state of evidence for use of neuromodulation to improve PTSD symptoms

1 Hour CME Credit available Format: On-Demand Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKERS:
Sandeep Vaishnavi, MD, PhD
Dr. Sandeep Vaishnavi is a faculty network member of the Duke Institute for Brain Sciences (DIBS) and an adjunct associate in the Department of Medicine at Duke University. He is the president of the Center for Neuropsychiatry and Brain Stimulation (CNBS), an ARC Health practice. He is the co-author of the books, The Traumatized Brain: A Family Guide to Understanding Mood, Memory, and Behavior after Brain Injury and Healing the Traumatized Brain: Coping after Concussion and other Brain Injuries.

> > Register Now <<

The Great Potential of QPS for Optimizing rTMS Outcomes
2023-09-05 18:00 - 19:00 UTC
> > Register Now <<
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: The Great Potential of QPS for Optimizing rTMS Outcomes featuring Dr. Amanda Tiksnadi!
Transcranial magnetic stimulation (TMS) has been known as a novel technique to modulate brain neuronal activity non-invasively. The magnitude and direction of modulatory effects of rTMS critically depend on the chosen protocol variables, e.g. stimulation intensity, frequency, train length, intertrain-interval, total number of magnetic pulse, as well as the coil configuration, current direction, pulse waveform, and position of the coil with respect to the cortex. Several methods have been validated to increase the efficacy of rTMS, i.e., iTBS and cTBS. This presentation will cover a new emerging method of QPS (Quadripulse Stimulation) that has shown higher efficacy in motor cortical plasticity than the previous method. This method may solve some of the major obstacles in achieving treatment efficacy for “rTMS-resistant” patients.
At the end of this presentation, participants will be able to:

Describe the basics of Quadripulse Stimulation
Explain the efficacy of Quadripulse Stimulation on motor cortical plasticity
Discuss the potential of Quadripulse Stimulation for optimizing rTMS outcomes

1 Hour CME Credit available
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKERS:
Amanda Tiksnadi, MD, PhD

Dr. Amanda Tiksnadi is a neurologist at the Neurology Department, Faculty of Medicine, Universitas Indonesia. Her special interests are movement disorders, neurorestoration & neuroengineering, and non-invasive brain stimulation.
Dr. Tiksnadi is currently Chief of Neurorestoration Division, Dept. of Neurology, Fac. of Med. at Universitas Indonesia, Chief of Movement Disorder Division, Dept. of Neurology, Fac. of Med. at Universitas Indonesia, and Chief of Brain Stimulation and Neurorestoration Lab at Cipto Mangunkusumo Hospital, Jakarta as well as Universitas Indonesia Hospital, Depok.

> > Register Now <<

Anatomy of Theta Burst
2023-08-01 20:00 UTC
> > Register Now <<
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Anatomy of Theta Burst featuring Dr. Bob Sammons!
The presentation will review the Anatomy of Theta Burst. Theta burst is gaining popularity in both research and clinical practice but the fundamental differences with rTMS make it hard for many clinicians to understand. This presentation is designed to facilitate the understanding of and ability to explain theta burst in detail. After a brief review of how theta burst was discovered, the focus shifts to its clinical usage and advanced protocols. A review of continuous theta burst concludes the presentation.
Take advantage of our Q&A portion at the conclusion of the webinar!
At the end of this presentation participants will be able to:

understand why does the definition of theta burst contain both 5 Hz and 50 Hz
explain why theta burst was originally thought to be stronger and faster than rTMS
discuss how theta burst originated

1 Hour CME Credit available
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKERS:
Bob Sammons, MD, PhD, FCTMSS

Dr. Bob Sammons received a bachelors and master’s degree from Auburn University, a PhD in clinical psychology from the University of North Carolina at Greensboro, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in 1971. He practiced adult psychiatry in Grand Junction for 30+ years. He received training in Transcranial Magnetic Stimulation in 2006 from Dr. Alvaro Pascual-Leone, from Dr. Mark George in 2017 and returned to Harvard for Dr. Pascual-Leone’s intensive course in TMS in 2018. He is Medical Director for TMS Solutions with fourteen TMS offices in various locations in the West. He is on the national Clinical TMS Society Board of Directors, sits on three national committees and is Chairman of the 2022 Annual Meeting. He has been known to cook a little BBQ.

> > Register Now <<

Transcranial Magnetic Stimulation and Neuroplasticity
2023-07-11 18:00 - 19:00 UTC
> > Register Now <<
You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Transcranial Magnetic Stimulation and Neuroplasticity, featuring Dr. Sabrina Segal!
The field of transcranial magnetic stimulation is evolving with novel protocols to treat depression, and explorative studies to target other therapeutic avenues for mental health. This presentation will review the neuroplastic mechanisms that underly the therapeutic effects of TMS and explain the role of neuroplasticity in TMS-treated psychiatric and neurological conditions. This talk will also examine novel explorations for TMS and memory.
Don't miss out on our Q&A portion of the webinar!
At the end of this presentation, participants will be able to identify and understand the following:

Identify the neuroplastic mechanisms that underly the therapeutic effects of TMS
Describe the role of TMS and neuroplasticity in psychiatric and neurological conditions
Explore the therapeutic potential for TMS on neuroplastic mechanisms that underly memory

Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKER:
Sabrina Segal, PhD
Dr. Segal earned her Ph.D. in Neurobiology and Behavior from the University of California, Irvine in 2010 and her research on exercise and memory received international recognition in 2012. She completed a postdoctoral fellowship at UC Irvine, UC Irvine Medical School Department of Anesthesiology and Children’s Hospital of Orange County (CHOC) from 2010-2014. She was a Research Professor at Arizona State University from 2014-2016, and has taught courses in biology, psychology, and neurobiology at colleges and military bases in California, Colorado and Arizona. Her research has focused on memory consolidation and enhancement via neuroplastic mechanisms.
She is extremely passionate about neuroscience research, the application of research to clinical practice, and improving education for mental health providers. In 2016, Dr. Segal joined the Neuroscience Education Institute, a continuing medical education company founded by world-renowned psychiatrist Dr. Stephen Stahl, where she developed high quality educational material based on the most current neuroscience research for mental health providers globally. She specialized in neurostimulation techniques like transcranial magnetic stimulation (TMS). Dr. Segal has published many scientific peer-reviewed journal articles, and several books. She is the author of: Beyond the Impact: An Update on the Assessment, Prevention, and Treatment of Neuropsychiatric Sequelae Associated with Traumatic Brain Injury and Stahl’s Illustrated: Treatments for Mood Disorders. She was also the host for the Neuroscience Education Institute podcast, where she published nearly 200 episodes on psychiatry and related mental health topics.
She is most passionate about the clinical application of TMS research, and she recently collaborated on TMS research with Dr. Robert Sammons, which was presented as an abstract poster at the CTMSS meeting in May 2023. Dr. Segal is currently Director of Research at Family Care Center, a multi-state integrative mental health clinic that combines therapy, medication management and transcranial magnetic stimulation.
> > Register Now <<

How to Understand the Exploding Evidence on New Circuit-Based TMS Targets
2023-06-06 20:00 - 21:00 UTC
You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: How to Understand the Exploding Evidence on New Circuit-Based TMS Targets, featuring Shan Siddiqi, MD!
We are currently in the midst of a rapid growth of evidence on new circuit-based TMS targets. This leaves the clinician with a challenging conundrum. When is the evidence strong enough to use a target clinically? When there is no clinical trial, can we learn from cohort studies? How valuable are lesion studies or functional neuroimaging studies? And how do I bring together all of this information to give my patient the best possible treatment? Fortunately, we don’t need to reinvent the wheel - there are several guidelines on how to weigh evidence across medicine. In this session, we will discuss how to apply these guidelines to circuit-targeted brain stimulation.
Take advantage of our Q&A portion of the webinar!
At the end of this presentation, participants will be able to identify and understand the following:

Describe emerging approaches for targeting brain circuits with TMS
Appraise evidence for emerging circuit-based treatment targets
Identify treatment targets that have strong evidence-based support

Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKER:
Shan Siddiqi, MD

Dr. Siddiqi’s research is focused on mapping new TMS targets for neuropsychiatric disorders based on causal mapping of human brain function and dysfunction. Using techniques such as functional connectivity MRI, his lab maps brain circuits to link brain lesions and brain stimulation sites that can modify different psychiatric symptoms. These circuits can then be targeted with treatments such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) to alleviate psychiatric symptoms. His work has been recognized with multiple awards from the Brain & Behavior Research Foundation, the American Neuropsychiatric Association, the American College of Neuropsychopharmacology, Harvard Medical School, and many others.

Deep TMS with the H7 Coil over the Dorsomedial PFC
2023-04-04 20:00 - 21:00 UTC
You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Deep TMS with the H7 Coil over the dorsomedial PFC, featuring Aron Tendler, MD!
The presentation will explain the physical capabilities and limitations of the current commercially available coils and how they relate to areas of stimulation. This presentation will also explain the level of available evidence with the H7 for OCD, MDD, Alcohol Use Disorder and cocaine.
Take advantage of our Q&A portion at the conclusion of the webinar!
At the end of this presentation, participants will be able to identify and understand the following:

Physical capabilities of the commercially available coils using electrical field measurements and simulations
Evidence for H7 and other coils for the treatment of OCD
Evidence for H7 and other coils for the treatment of MDD
Evidence for H7 and other coils for the treatment of Addictions

Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKER:
Aron Tendler, MD

Dr. Aron Tendler is board certified in general psychiatry, sleep medicine, and obesity medicine. He sees patients thirty hours a week, in his private practice and spends thirty hours a week on research and education as the Chief Medical Officer for BrainsWay.
Dr. Tendler's private practice is focused on helping patients who want to improve their functioning and are willing to change their treatment regimen when they are not doing well.
Dr. Tendler's research over the last twelve years has advanced the field of psychiatry forward by gaining regulatory clearance and reimbursement with effective brain-based treatments for patients with depression and obsessive compulsive disorder. He believes a greater understanding of physics and neuroscience will improve patient care and reduce stigma for patients with all neuropsychiatric disorders.

Emerging Transcranial Ultrasound Neuromodulation Technologies
2023-03-07 20:00 - 21:00 UTC
You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Emerging Transcranial Ultrasound Neuromodulation Technologies, featuring Hong Chen!
Transcranial ultrasound neuromodulation is an emerging technology with increasing clinical investigations. Ultrasound can penetrate the skull without surgery and focus its energy with high spatial precision anywhere in the brain. In addition, ultrasound neuromodulation has the unique capability to achieve noninvasive, spatially targeted, and deep brain neuromodulation. This talk will introduce the state of the art of ultrasound neuromodulation and discuss emerging technology developments in this field.
Take advantage of our live Q&A session at the conclusion of the webinar!
At the end of this presentation, participants will be able to identify the following:

What is transcranial ultrasound neuromodulation
Why this technology is the state of the art
Emerging technology developments

Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKER:
Hong Chen, PhD

Dr. Chen is a world-leading scientist in developing innovative therapeutic ultrasound technologies and an Associate Professor of Biomedical Engineering at Washington University in St. Louis. She earned her Ph.D. degree in Bioengineering from the University of Washington in 2011. Dr. Chen was a postdoctoral research scientist in the Department of Biomedical Engineering at Columbia University from 2012 to 2015. Since joining Washington University in St. Louis in 2015, her research has focused on developing ultrasound-brain interfacing techniques for diagnosing and treating brain diseases and understanding brain functions. Her research has been funded by NIH BRAIN Initiative, NIBIB, NIA, NIMH, NCI, NSF, and DoD.
She currently serves on the Board of Directors for the International Society of Therapeutic Ultrasound, the IEEE International Ultrasonics technical committee, and the Acoustical Society of America Biomedical Ultrasound technical committee. She has received numerous awards, including the Frederic Lizzi Early Career Award from the International Society of Therapeutic Ultrasound, the Young Investigator Award at the International Symposium on Focused Ultrasound, and Outstanding Teaching Award.

rTMS for Pain: From Clinical Guidelines to Practical Challenges
2023-02-07 20:00 - 21:00 UTC
This presentation will overview the current rTMS treatment guidelines for pain, review various challenges related to the treatment for pain and headache management, and discuss measures to overcome these highly relevant issues.
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: rTMS for Pain: From Clinical Guidelines to Practical Challenges, featuring Albert Leung, MD!
Emerging evidence supports the use of rTMS for pain and headache management. However, pain and headache rTMS treatment protocols differ in many ways from those used for depression or other psychiatric conditions. In the upcoming Grand Round presentation, Dr. Leung, a pain specialist, Professor of Anesthesiology and Pain Medicine, will overview the current rTMS treatment guideline for pain and review various challenges related to the treatment for pain and headache management and discuss measures to overcome these highly relevant issues.
Don't miss out on our Q&A portion of the webinar!
At the end of this presentation, participants will be able to identify:

The current clinical rTMS treatment guidelines for headache and pain;
Review practice-related issues using rTMS for pain and headache;
Discuss measures and identify resources to address these highly relevant issues.

Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKER:
Albert Y. Leung, MD

Dr. Leung is a Professor of Anesthesiology and Pain Medicine at the University of California, San Diego, School of Medicine. In addition, he is the Director of the Center for Pain and Headache Research at the VA San Diego Healthcare System (VASDHS) and a Research Scientist for the Veteran Medical Research Foundation.
Dr. Leung receives funding from the DOD, VA Office of Research and Development, and NIH for his ongoing research focusing on the mechanisms and effectiveness of non-invasive brain and peripheral stimulation for nerve function restoration and headache/pain relief. He founded the first Transcranial Magnetic Stimulation (TMS) clinical unit for pain and headache treatment in the VA healthcare system over a decade ago. He now directs the Center for TMS at the VASDHS.
